Salmeterol Xinafoate: An Analysis of Outcomes and Cost-Effectiveness Using a Primary Care Database

David Price, K. CARGILL, S. Wolfe, H. DARBY

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Long-acting inhaled /&-agonists (LABS), used in conjunction with low-dose inhaled steroids, are a recommended alternative to high-dose inhaled steroids for asthmatics with persistent symptoms (1). There are, however, few published data regarding their cost-effectiveness. The drugs are relatively expensive and the aim of this study was to evaluateLAB cost-effectiveness in primary care, in terms of improved clinical outcomes (associated with reduced NHS costs) offsetting higher prescription costs. A controlled, retrospective, non-randomized analysis utilized the computerized Thorpewood Primary Care Database and compared clinical outcomes and asthma management costs 1 yr prior to and 1 yr after initiation of therapy with salmeterolxinafoate.
Original languageEnglish
Pages (from-to)1302-1304
Number of pages3
JournalRespiratory Medicine
Volume92
DOIs
Publication statusPublished - 1998

Fingerprint Dive into the research topics of 'Salmeterol Xinafoate: An Analysis of Outcomes and Cost-Effectiveness Using a Primary Care Database'. Together they form a unique fingerprint.

  • Cite this